- Delivering Pan India
Renfor® (Mycophenolic Acid) Mycophenolic acid 360 mg delayed-release tablets by Abbott. Genuine stock supplied in bulk/wholesale quantities to hospitals and pharmacies across India by A.K. Pharma, a licensed pharmaceutical distributor in Delhi.
| Composition | Mycophenolic acid 360 mg |
|---|---|
| Manufacturer | Abbott |
| Country | India |
| Pack size | Mycophenolic acid 360 mg: 1 x 10 tablets (as shown on the carton) |
| Storage | Store as per the carton; the US reference label describes 20°C to 25°C. |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Renfor® (Mycophenolic Acid) Mycophenolic acid 360 mg Delayed-Release Tablets — Mycophenolic Acid Delayed-Release Tablets USP: A Sourcing Guide for Hospitals and Pharmacies
Renfor® is a brand of mycophenolic acid delayed-release tablets USP 360 mg marketed in India by Abbott, shown on the carton as a pack of 1 x 10 tablets. According to the current US prescribing information for the reference product Myfortic, mycophenolic acid is an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adults receiving kidney transplants and in pediatric patients aged 5 years and older who are at least 6 months post kidney transplant, in combination with cyclosporine and corticosteroids. Indications in India are defined by its approved pack insert and the Indian regulator. The decision to prescribe mycophenolic acid, including patient selection, dose and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Renfor® (mycophenolic acid) Mycophenolic acid 360 mg delayed-release tablets to hospitals and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the immunosuppressant medicines category. Supply is in bulk/wholesale quantities only.
Renfor contains mycophenolic acid 360 mg, as delayed-release tablets, supplied in the pack size listed below.
How it works, according to the label: The reference label describes mycophenolic acid as an antimetabolite immunosuppressant that inhibits inosine monophosphate dehydrogenase and so the proliferation of T and B lymphocytes.
The current US prescribing information for Myfortic® (mycophenolic acid) delayed-release tablets (DailyMed) lists the following. Indications in India may differ and are defined by the Indian regulator and the Renfor pack insert.
The reference label summarises its Clinical Studies in kidney transplant recipients, comparing Myfortic with mycophenolate mofetil in de novo and maintenance transplant populations. A published comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in de novo renal transplantation (Sollinger et al., Transplantation Proceedings, 2004) is listed below. Evidence is cited for information only and is not a recommendation for any patient; the approved prescribing information governs.
| Strength | Dosage form | Pack size (as shown on the carton) |
|---|---|---|
| Mycophenolic acid 360 mg | Delayed-release tablets USP | 1 x 10 tablets (as shown on the carton) |
Please confirm the current pack and batch with us before ordering. Dose and regimen must be determined and followed exactly as directed by the treating physician and the approved prescribing information.
This page is written for transplant centre pharmacists, nephrology department buyers and pharmacies that source immunosuppressant products. Mycophenolic acid is prescribed and supervised by a physician experienced in immunosuppressive therapy, as described in the prescribing information.
The reference label carries a boxed warning for embryo-fetal toxicity, malignancies and serious infections. It lists anaemia, leukopenia, constipation, nausea, diarrhoea, vomiting, dyspepsia, urinary tract infection, CMV infection, insomnia and postoperative pain among the most common adverse reactions (20% or more). This list is not complete; the full prescribing information governs.
All use should follow the approved prescribing information and the instructions of the treating physician.
Please follow the storage instructions printed on the Renfor carton and blister. For reference, the US Myfortic label describes storage at 20°C to 25°C. Keep out of reach of children.
Renfor is marketed by Abbott. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Renfor through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Renfor available in India?
A.K. Pharma supplies Renfor (mycophenolic acid) Mycophenolic acid 360 mg delayed-release tablets to hospitals and pharmacies in India. Contact us for current availability.
What does Renfor contain?
Mycophenolic acid, an antimetabolite immunosuppressant, as 360 mg delayed-release tablets.
Can I order a single pack?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
How should Renfor be stored?
Follow the carton and blister; the US reference label describes 20°C to 25°C.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
